# US 2015/0104458 A1 · House dust mite allergen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104458 A1
- Document ID: US20150104458A1
- Status: Published application
- Kind: A1
- Application number: 14/468,499
- Filed: 2014-08-26
- Published: 2015-04-16
- Earliest claimed: 2006-04-28
- Assignees: Biomay AG
- Applicants: Biomay AG
- Inventors: Rudolf VALENTA; Margit Weghofer; Susanne Vrtala; Friedrich Horak; Peter Valent; Stefan Florian
- Web page: https://patentgrep.com/patent/US20150104458A1

## CPC

- C07K 14/43531: {from mites}
- A61K 39/35: Allergens
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 16/18: against material from animals or humans
- C07K 17/08: the carrier being a synthetic polymer
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/43582: from mites
- G01N 2800/24: Immunology or allergic disorders
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.

## Claims

### Claim 1

A polypeptide comprising an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or comprising at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least on T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.

### Claim 2 (depends on 1)

Polypeptide according to claim 1, characterised in that the amino acid sequence is at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95%, in particular 100%, identical to the amino acid sequence SEQ ID No. 1.

### Claim 3 (depends on 1, 2)

Polypeptide according to claim 1 or 2, characterised in that said polypeptide is hypoallergenic.

### Claim 4 (depends on 1, 2, 3)

Polypeptide according to any one of claims 1 to 3, characterised in that said amino acid:fragments are fused together in an order differing from the order of said fragments in SEQ ID No. 1.

### Claim 5 (depends on 1, 2, 3, 4)

Polypeptide according to any one of claims 1 to 4, characterised in that said at least one amino acid fragment is selected from the group consisting of amino acid molecules comprising amino acids 5 to 13, 9 to 17, 10 to 18, 11 to 19, 12 to 20, 16 to 24, 17 to 25, 43 to 51, 44 to 52, 45 to 53, 47 to 55, 51 to 59 and 60 to 68 of SEQ ID No. 1.

### Claim 6 (depends on 1, 2, 3, 4, 5)

DNA molecule encoding a polypeptide according to any one of claims 1 to 5.

### Claim 7 (depends on 5)

Vector comprising a DNA molecule according to claim 5.

### Claim 8 (depends on 6)

Cell transformed with a vector according to claim 6.

### Claim 9 (depends on 1, 2, 3, 4, 5)

Antibody binding to a polypeptide according to any one of claims 1 to 5.

### Claim 10 (depends on 1, 2, 3, 4, 5, 9)

Vaccine formulation comprising a polypeptide according to any one of claims 1 to 5 or an antibody according to claim 9.

### Claim 11 (depends on 1, 2, 3, 4, 5)

Use of a polypeptide according to any one of claims 1 to 5 for the diagnosis of an allergy, in particular of house dust mite allergy, in an individual.

### Claim 12 (depends on 1, 2, 3, 4, 5, 9)

Use of a polypeptide according to any one of claims 1 to 5 or an antibody according to claim 9 for the preparation of a medicament for the immunotherapy of an allergy, in particular of house dust mite allergy.

### Claim 13 (depends on 1, 2, 3, 4, 5, 9)

Use of a polypeptide according to any one of claims 1 to 5 or an antibody according to claim 9 for the preparation of a medicament for the prevention of an allergen sensitisation, in particular of house dust mite allergen sensitisation.

### Claim 14 (depends on 12, 13)

Use according to claim 12 or 13, characterized in that said medicament further contains adjuvants, diluents, preservatives or mixtures thereof.

### Claim 15 (depends on 12, 13, 14)

Use according to any one of claims 12 to 14, characterized in that the medicament comprises 10 ng to 1 g, preferably 100 ng to 10 mg, especially 0.5 μg to 200 μg of Said polypeptide.
